Age and sex dependent pharmacokinetics of cyclosporine in the rat after a single intravenous dose

International Journal of Pharmaceutics

Volumn 174, Issue 1-2, 1998, Pages 9-18

  Molpeceres, J ^a   Chacon M ^a   Berges, L ^a   Pedraz, J L ^b   Guzman M ^a   Aberturas, M R ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Age; Cyclosporine; Intravenous; Pharmacokinetics; Rat; Sex

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE;

EID: 0031734192     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00198-7     Document Type: Article

References (41)

1. Awni W.M., Heim-Duthoy K., Kasiske B.L. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. Transplant. Proc. 22:1990;1193-1196.
2. Bernareggi A., Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J. Pharmacokinet. Biopharm. 19:1991;21-50.
3. Bonduelle S., Pimienta C., Benoit J.P., Lenaerts V. Body distribution in mice of intravenously injected radiolabelled cyclosporin associated with polyisohexylcyanoacrylate nanocapsules or nanospheres. Eur. J. Pharm. Biopharm. 41:1995;27-30.
4. Brunner L.J., Bennet W.M., Koop D.R. Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity. J. Pharm. Exp. Ther. 277:1996;1710-1718.
5. Fahr A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24:1993;472-495.
6. Gibaldi, M., Perrier, D., 1982. Farmacocinética. Reverté, Barcelona, pp 47-98.
7. Gleiter C.H., Gundert-Remy U. Gender differences in pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet. 21:1996;123-128.
8. Grevel J., Reynolds K.L., Rutzky L.P., Kahan B.D. Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. J. Clin. Pharmacol. 29:1989;261-266.
9. Grevel J., Napoli K.L., Kahan B.D. Covariables in cyclosporine immunosuppression. Transplant. Proc. 22:1990;1113-1115.
10. Guzman M., Molpeceres J., Garcia F., Aberturas M.R., Rodríguez M. Formation and characterization of cyclosporine-loaded nanoparticles. J. Pharm. Sci. 82:1993;498-502.
11. Harris R.Z., Benet L.Z., Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 50:1995;222-239.
12. Hirasawa K., Kamada N. Female sex hormone, estradiol, antagonizes the immunosuppressive activity of cyclosporine in rat organ transplantation. Transplant. Proc. 24:1992;408-409.
13. Humbert H., Guest G., Said M.B., Cabiac M.D., Gagnadoux M.F., Niaudet P., Broyer M. Steady-state pharmacokinetics of cyclosporine in renal transplant patients: does an influence of age or body weight exist? Transplant. Proc. 26:1994;2791-2797.
14. IFFA-CREDO, 1988. Données biologiques rat Wistar, IFFA-CREDO Ed., L'Arbresle, p 7.
15. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 43:1991;287-289.
16. Kolars J.C., Stetson P.L., Rush B.D., Ruwart M.J., Schmiedlin-Ren P., Duell E.A., Voorhees J.J., Watkins P.B. Cyclosporine metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? Transplantation. 53:1992;596-602.
17. Kuster G.M., Drexel H., Bleisch J.A., Rentsch K., Pei P., Binswanger U., Amann F.W. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 57:1994;1479-1483.
18. Lemaire M., Fahr A., Maurer G. Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplant. Proc. 22:1990;1110-1112.
19. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther. Drug Monit. 13:1991;465-477.
20. Lindholm A., Welsh M., Rutzky L., Kahan B.D. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. Transplantation. 55:1993;985-993.
21. Lum B.L., Tam J., Kaubisch S., Flechner S.M. Arithmetic versus harmonic mean values for cyclosporin-A pharmacokinetic parameters. J. Clin. Pharmacol. 32:1992;911-914.
22. Malmary M.F., Houti I., Labat C., Batalla A., Moussamih S., Bouguettaya D., Oustrin J., Houin G. Chronopharmacokinetics of cyclosporine A following a single i.v. dose in the Wistar rat. Eur. J. Pharm. Sci. 3:1995;49-56.
23. Masri M.A., Dhawan V.S.I.K., Hayes K., Karim T., Pingle A. Cyclosporine dosage according to pharmacokinetic profiles leads to better graft and patient survival rates and a decrease in cyclosporine consumption. Transplant. Proc. 24:1992;1718-1720.
24. Molpeceres J., Guzmán M., Bustamante P., Aberturas M.R. Exothermic-endothermic heat of solution shift of cyclosporin A related to poloxamer 188 behavior in aqueous solutions. Int. J. Pharm. 130:1996;75-81.
25. Mraz W., Modic P.K., Hammer C. Impact of Imipenem/cilastatin on cyclosporine metabolism and excretion. Transplant. Proc. 24:1992;1704-1708.
26. Mueller E.A., Kovarik J.M., Van Bree J.B., Tetzloff W., Grevel J., Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 11:1994;301-304.
27. Perotti B.Y.T., Okudaira N., Prueksaritanont T., Benet L.Z. FK 506 metabolism in male and female rat liver microsomes. Drug Metab. Dispos. 22:1994;85-89.
28. Plant N.D., Milford D.V., Jones S.R. Cyclosporine profiles in children following renal transplantation. Transplant. Proc. 26:1994;85-87.
29. Prueksaritanont T., Correia M.A., Rettie A.E., Swinney D.C., Thomas P.E., Benet L.Z. Cyclosporine metabolism by rat liver microsomes: evidence for involvement of enzyme(s) other than cytochromes P450 3A. Drug Metab. Dispos. 21:1993;730-737.
30. Rödl S., Khoshsorur G. Binding of cyclosporine A to human serum lipoproteins. Transplant. Proc. 22:1990;287-288.
31. Sadrieh N., Thomas P.E. Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins. Tox. Appl. Pharmacol. 127:1994;222-232.
32. Sanchez A., Alonso M.J. Poly(D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A. Eur. J. Pharm. Biopharm. 41:1995;31-37.
33. Sangalli L., Bortolotti A., Jiritano L., Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab. Dispos. 16:1988;749-753.
34. Schroeder T.J., Hariharan S., First M.R. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant. Proc. 27:1995;837-839.
35. Shibata N., Shimakawa H., Minouchi T., Yamaji A. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol. Pharm. Bull. 16:1993;1130-1135.
36. Shibata N., Yamaji A., Park K., Tomoyoshi T., Sako H., Abe H., Kodama M., Nakane Y., Hodohara K., Hosoda S. A simple method for predicting the cyclosporin A erythrocyte-to-plasma distribution ratio in blood, and its clinical assessment. Biol. Pharm. Bull. 17:1994;709-714.
37. Smith D.A. Species differences in metabolism and pharmacokinetics: Are we close to an understanding? Drug Metab. Rev. 23:1991;355-373.
38. Vadiei K., Perez-Soler R., Lopez-Berenstein G., Luke D.R. Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine. Int. J. Pharm. 57:1989;125-131.
39. Vonderscher J., Meinzer A. Rationale for the development of sandimmune neoral. Transplant. Proc. 26:1994;2925-2927.
40. Wagner, J.G., 1979. Fundamentals of Clinical Pharmacokinetics. Drug Intelligence, Hamilton, IL, pp 359-395.
41. Yee G.C. Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation. Transplant. Proc. 22:1990;1327-1330.